NDA 208772 · Takeda Pharms USA
Alunbrig
Brigatinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Feb 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Apr 28, 2017
Approved uses
4
Original approval plus efficacy supplements
Registered trials
34
2 Phase 3, 8 recruiting
FAERS reports
3,655
3,259 serious, 788 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 12, 2026.
ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1 , 2.1 )
Mechanism: Brigatinib is a tyrosine kinase inhibitor (TKI) with in vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations. Brigatinib inhibited autophosphorylation of ALK and ALK-mediated phosphorylation of the downstream signaling proteins STAT3, AKT, ERK1/2, and S6 in in vitro and in vivo assays. Brigatinib also inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of...
Therapeutic areas: Oncology · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 28, 2022 Supplement 13 · Efficacy OrphanLetterLabel
- May 22, 2020 Supplement 8 · Efficacy · priority review OrphanLabelLetter
- Dec 21, 2018 Supplement 4 · Efficacy OrphanLabelLetter
- Apr 28, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
3 products under this application
- ALUNBRIG · BRIGATINIB 180MG · TABLET, ORAL · Prescription
- ALUNBRIG · BRIGATINIB 30MG · TABLET, ORAL · Prescription
- ALUNBRIG · BRIGATINIB 90MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Brigatinib" as an intervention, any sponsor and status, largest first.
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
Nuvalent Inc.Industry
NCT05384626 · 840 participants (planned) · Start Jun 9, 2022 · Primary completion Dec 2027
Drug: Neladalkib (NVL-655); Midazolam and 2 more · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Orange, California; Sacramento, California; Stanford, California · 74 sites in all
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyPivotal-lookingStatus unknown
Fondazione per la Medicina PersonalizzataAcademic, hospital or other
NCT04591431 · 400 participants · Start Oct 7, 2020 · Primary completion Dec 2024
Drug: Erlotinib; Trastuzumab and 24 more · For: Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer and 1 more
Sites: Ancona, Italy; Aviano, Italy; Bari, Italy · 37 sites in all
- ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsPivotal-lookingCompleted
Ariad PharmaceuticalsTakeda (TAK)
NCT02737501 · 275 participants · Start May 26, 2016 · Primary completion Jul 28, 2020
Drug: Brigatinib; Crizotinib · For: Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies and 1 more
Sites: Sedona, Arizona; Bellflower, California; Aurora, Colorado · 91 sites in all
- A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung CancerPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT03596866 · 248 participants · Start Apr 19, 2019 · Primary completion Feb 27, 2024
Drug: Brigatinib; Alectinib · For: ALK+ Advanced NSCLC
Sites: Whittier, California; Athens, Georgia; Albany, New York · 114 sites in all
- A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibPivotal-lookingCompleted
Ariad PharmaceuticalsTakeda (TAK)
NCT02094573 · 222 participants · Start Jun 4, 2014 · Primary completion Feb 29, 2016
Drug: Brigatinib · For: Carcinoma, Non-Small-Cell Lung
Ariad PharmaceuticalsTakeda (TAK)
NCT01449461 · 137 participants · Start Sep 20, 2011 · Primary completion Nov 16, 2015
Drug: Brigatinib · For: Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung
- Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep PhenotypingPivotal-lookingCompleted
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestAcademic, hospital or other
NCT04318938 · 118 participants · Start Mar 30, 2020 · Primary completion May 30, 2026
Drug: Brigatinib; Tyrosine kinase inhibitor · For: NSCLC
Sites: Berlin, Germany; Cologne, Germany; Essen, Germany · 26 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death431
- non-small cell lung cancer396
- off label use307
- diarrhoea255
- metastases to central nervous system242
- nausea234
- lung neoplasm malignant225
- blood creatine phosphokinase increased220
- fatigue216
- product dose omission issue204
- drug ineffective185
- neoplasm progression180
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 57 |
| 2018 | 244 |
| 2019 | 310 |
| 2020 | 374 |
| 2021 | 526 |
| 2022 | 579 |
| 2023 | 486 |
| 2024 | 541 |
| 2025 | 377 |
| 2026 | 160 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Alunbrig (Brigatinib)
2024 spending
$41.9M
Beneficiaries
323
2,175 claims
Per beneficiary
$129,681
$564.90 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $15,825,268 |
| 2021 | $19,416,970 |
| 2022 | $27,828,145 |
| 2023 | $33,349,882 |
| 2024 | $41,887,107 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR, Kim HR, Ahn MJ, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors.
Plotkin SR, Yohay KH, Nghiemphu PL, et al. · N Engl J Med 2024 · Clinical Trial, Phase II, Multicenter Study
- Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).
Ou SH, Kilvert H, Candlish J, et al. · Lung Cancer 2024 · Systematic Review, Comparative Study
- Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
Camidge DR, Kim HR, Ahn MJ, et al. · J Thorac Oncol 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons.
Garcia C, Abrahami D, Polli A, et al. · Clin Lung Cancer 2024 · Comparative Study, Clinical Trial, Phase III
- Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
Ahn MJ, Kim HR, Yang JCH, et al. · Clin Lung Cancer 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.